Keywords: Isis, Astrazeneca, ISIS-STAT3Rx, antisense, lymphoma

Isis on a roll as it signs another licence deal

Article | 12 December 2012

Print This

With the ink barely dry on its $630 million deal with Biogen Idec (The Pharma Letter December 11),antisense specialist Isis Therapeutics ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in